Differing Effects of Metformin on Glycemic Control by Race-Ethnicity
Year: 2014
Type: article
Study design: Observational Study
Abstract: CONTEXT: Metformin is considered first-line treatment for type 2 diabetes mellitus. However, little is known about its effects in African American individuals. OBJECTIVE: The objective of the study was to assess whether metformin's effect on glycemic control differs by race-ethnicity Design: Electronic health records were used to identify adults who had a diagnosis of diabetes, two or more fills of metformin, and two or more glycated hemoglobin (HbA1c) measurements. Pharmacy claims were used to estimate metformin exposure based on fill frequency and dose dispensed. Regression analyses modeled the relationship between metformin exposure and HbA1c levels. Analyses were stratified by race-ethnicity and baseline HbA1c values. SETTING: The study was conducted at a large health system in southeast Michigan. MAIN OUTCOME MEASURE: Differences in HbA1c levels while on metformin were measured. RESULTS: We identified 19 672 patients with diabetes taking metformin; 7429 were African American and 8783 were European American. Baseline HbA1c values in these two groups were 7.81% (61.8 mmol/mol) and 7.38% (57.1 mmol/mol), respectively. Compared with no use, metformin was associated with a 0.62% (6.8 mmol/mol) reduction in HbA1c; however, there was a significant difference by race-ethnicity (P < .001). Among African American individuals, metformin use was associated with a 0.90% (9.8 mmol/mol) reduction in HbA1c levels, whereas among European Americans, metformin was associated with a 0.42% (4.6 mmol/mol) reduction. Irrespective of baseline HbA1c, metformin use was associated with lower HbA1c levels in African American individuals. CONCLUSIONS: African American individuals appear to have a better glycemic response to metformin when compared with European Americans. Further studies are needed to determine whether this translates to commensurate reductions in diabetes complications.
DOI: 10.1210/jc.2014-1539
Institutions: Henry Ford Health, University of California, San Francisco
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Pharmacogenetics of the B-type Natriuretic Peptide Pathway, Leveraging electronic medical records to perform large-scale diabetes pharmacogenomics among ancestrally diverse patient populations, PHARMACOGENOMICS OF INHALED CORTICOSTEROID RESPONSIVENESS IN PATIENTS WITH ASTHMA, USING INFORMATION TECHNOLOGY TO IMPROVE ASTHMA ADHERENCE, Combined Transcriptomics and Genomics to Find Asthma Genes in Admixed Populations, The Clinical Effectiveness of Pharmacy Adherence Information for Diabetes Control, Impact of Race and Genetic Factors on Beta-blocker Effectiveness in Heart Failure
OpenAlex ID: W2152817207
